Download Files:
Products Details
Product Description
– Topiramate (McN 4853) lithium is a broad-spectrum antiepileptic agent. Topiramate lithium is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase[1][2][3].
Web ID
– HY-B0122A
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C12H21LiNO8S
References
– [1]Kaminski RM, et al. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004 Jun;46(8):1097-104.|[2]Lyseng-Williamson KA, et al. Topiramate: a review of its use in the treatment of epilepsy. Drugs. 2007;67(15):2231-56.|[3]Nakamura J, et al. Target pharmacology of topiramate, a new antiepileptic drug. Nihon Yakurigaku Zasshi. 2000 Jan;115(1):53-7.
CAS Number
– 488127-53-3
Molecular Weight
– 346.30
SMILES
– NS(OC[C@]1(OC(C)(C)O2)[C@@H]2[C@H](OC(C)(C)O3)[C@H]3CO1)(=O)=O.[Li]
Clinical Information
– Launched
Research Area
– Neurological Disease
Solubility
– 10 mM in DMSO
Target
– Calcium Channel;Carbonic Anhydrase;GABA Receptor;iGluR;Potassium Channel;Sodium Channel
Isoform
– AMPA Receptor;Kainate Receptor
Pathway
– Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
